MS News That Caught My Eye Last Week: ODRS Test, Kesimpta, Coping Strategies, Dual Tasking
Columnist Ed Tobias comments on the week's top MS news
Adding two other disability measurements to the commonly used Expanded Disability Status Scale (EDSS) is a good idea, not only for trials but also in everyday patient assessments as well. Measuring our level of disability using only the EDSS, which is mainly based on maximum walking distance without assistance, fails to take into account the impact that weakened upper-body strength and cognitive problems have on the quality of life for people with MS. Using the more complete Overall Disability Response Score (ODRS) to judge outcomes in clinical trials is a step in the right direction.
The Overall Disability Response Score, a combination of three different assessments of disability, could be used to more accurately evaluate the effectiveness of treatments in multiple sclerosis (MS) clinical trials, a new study illustrates.
The score is composed of three measures commonly used to assess disability in MS, which evaluate hand dexterity, walking ability, and overall disability.
I have no evidence this study is anything less than straight-up, but I always have to think twice when I read of a study that reports a DMT is better and less expensive than others. And then I see that the study was paid for by the manufacturer of that DMT. Am I wrong to be suspicious?
Kesimpta (ofatumumab) is more cost-effective for treating relapsing-remitting multiple sclerosis (RRMS) than most other disease-modifying therapies (DMTs) approved in Canada, according to a new analysis.
The analysis indicated that Kesimpta is generally more effective and associated with fewer costs than the majority of MS treatments, with the exception of glatiramer acetate. However, while glatiramer acetate — sold as Copaxone, with generics also available — did have fewer costs, it was less effective.
As I surf across multiple sclerosis social sites, I regularly read of people, particularly those newly diagnosed, who cope with MS by avoiding or denying it. My coping strategy has always been to accept that I have MS and try to do as much as I can, in terms of medication and exercise, to live with it. What’s your coping strategy?
People with multiple sclerosis (MS) may be more likely to use unhealthy or ineffective coping mechanisms than healthy individuals — and these “maladaptive strategies” are linked to worse mood and a poorer quality of life among patients, according to a new review study.
Rather than also relying on active coping strategies, like seeking social support or creating positive meaning, patients tended to use only more passive strategies, like denial or simply not dealing with stressful situations and emotions. Such avoidance, however, is associated with increased depression, anxiety, fatigue, and a worse quality of life in MS patients.
It’s not quite like walking and chewing gum at the same time, but it doesn’t seem far off. In this study, subjects were asked to stand still with their eyes closed, or walk a short distance, while trying to complete a cognitive test at the same time. This dual tasking appeared more difficult for people with MS than for healthy folks. It’s hoped this knowledge will lead to interventions that can correct this deficit.
Even in early stages of disease, people with multiple sclerosis (MS) commonly experience more difficulties performing cognitive and motor tasks simultaneously than do people without MS, a new study indicates.
Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Multiple Sclerosis News Today or its parent company, BioNews, and are intended to spark discussion about issues pertaining to multiple sclerosis.